Islet allotransplantation in type 1 diabetic patients.

F. Bertuzzi, P. Maffi, R. Nano, L. Aldrighetti, B. Clissi, R. Melzi, B. Antonioli, S. Marzorati, A. M. Davalli, A. Secchi, V. Di Carlo

Research output: Contribution to journalArticle

Abstract

Islet transplantation was proposed more than 10 years ago as treatment for normalising glucose homeostasis in type 1 diabetic patients. Since the beginning it has aroused great interest among diabetic patients being an easy procedure, burdened by minor complications: islet transplantation in fact consists on a transhepatic percutaneous injection under local anaesthesia. The initial clinical outcomes not came up to expectations, being low the insulin independence rate and the long term graft function in recipients. Recently, thanks to the introduction of new immunosuppression strategies, clinical data greatly improved: insulin independence was reached in all recipients and maintained in more than 70% of them 2 years from the transplant. The need of an immunosuppression therapy limits the indication of islet transplantation to diabetic patients already immunosuppressed for a previous organ transplant or to patients with brittle diabetes, that is not controlled also with the new strategies of insulin treatment, with a poor quality of life and an increased rate of diabetic complications. Other problems are represented by the progressive decrease of graft function during long term follow up, and by the low number of organ donors that limits the number of transplantation feasible per year.

Original languageEnglish
Pages (from-to)103-109
Number of pages7
JournalMinerva Endocrinologica
Volume28
Issue number2
Publication statusPublished - 2003

Fingerprint

Islets of Langerhans Transplantation
Transplants
Insulin
Immunosuppression
Local Anesthesia
Diabetes Complications
Homeostasis
Therapeutics
Transplantation
Quality of Life
Tissue Donors
Glucose
Injections

Cite this

Bertuzzi, F., Maffi, P., Nano, R., Aldrighetti, L., Clissi, B., Melzi, R., ... Di Carlo, V. (2003). Islet allotransplantation in type 1 diabetic patients. Minerva Endocrinologica, 28(2), 103-109.

Islet allotransplantation in type 1 diabetic patients. / Bertuzzi, F.; Maffi, P.; Nano, R.; Aldrighetti, L.; Clissi, B.; Melzi, R.; Antonioli, B.; Marzorati, S.; Davalli, A. M.; Secchi, A.; Di Carlo, V.

In: Minerva Endocrinologica, Vol. 28, No. 2, 2003, p. 103-109.

Research output: Contribution to journalArticle

Bertuzzi, F, Maffi, P, Nano, R, Aldrighetti, L, Clissi, B, Melzi, R, Antonioli, B, Marzorati, S, Davalli, AM, Secchi, A & Di Carlo, V 2003, 'Islet allotransplantation in type 1 diabetic patients.', Minerva Endocrinologica, vol. 28, no. 2, pp. 103-109.
Bertuzzi, F. ; Maffi, P. ; Nano, R. ; Aldrighetti, L. ; Clissi, B. ; Melzi, R. ; Antonioli, B. ; Marzorati, S. ; Davalli, A. M. ; Secchi, A. ; Di Carlo, V. / Islet allotransplantation in type 1 diabetic patients. In: Minerva Endocrinologica. 2003 ; Vol. 28, No. 2. pp. 103-109.
@article{9682cd67fd4f4d0b9578beb5702d9aa5,
title = "Islet allotransplantation in type 1 diabetic patients.",
abstract = "Islet transplantation was proposed more than 10 years ago as treatment for normalising glucose homeostasis in type 1 diabetic patients. Since the beginning it has aroused great interest among diabetic patients being an easy procedure, burdened by minor complications: islet transplantation in fact consists on a transhepatic percutaneous injection under local anaesthesia. The initial clinical outcomes not came up to expectations, being low the insulin independence rate and the long term graft function in recipients. Recently, thanks to the introduction of new immunosuppression strategies, clinical data greatly improved: insulin independence was reached in all recipients and maintained in more than 70{\%} of them 2 years from the transplant. The need of an immunosuppression therapy limits the indication of islet transplantation to diabetic patients already immunosuppressed for a previous organ transplant or to patients with brittle diabetes, that is not controlled also with the new strategies of insulin treatment, with a poor quality of life and an increased rate of diabetic complications. Other problems are represented by the progressive decrease of graft function during long term follow up, and by the low number of organ donors that limits the number of transplantation feasible per year.",
author = "F. Bertuzzi and P. Maffi and R. Nano and L. Aldrighetti and B. Clissi and R. Melzi and B. Antonioli and S. Marzorati and Davalli, {A. M.} and A. Secchi and {Di Carlo}, V.",
year = "2003",
language = "English",
volume = "28",
pages = "103--109",
journal = "Minerva Endocrinologica",
issn = "0391-1977",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "2",

}

TY - JOUR

T1 - Islet allotransplantation in type 1 diabetic patients.

AU - Bertuzzi, F.

AU - Maffi, P.

AU - Nano, R.

AU - Aldrighetti, L.

AU - Clissi, B.

AU - Melzi, R.

AU - Antonioli, B.

AU - Marzorati, S.

AU - Davalli, A. M.

AU - Secchi, A.

AU - Di Carlo, V.

PY - 2003

Y1 - 2003

N2 - Islet transplantation was proposed more than 10 years ago as treatment for normalising glucose homeostasis in type 1 diabetic patients. Since the beginning it has aroused great interest among diabetic patients being an easy procedure, burdened by minor complications: islet transplantation in fact consists on a transhepatic percutaneous injection under local anaesthesia. The initial clinical outcomes not came up to expectations, being low the insulin independence rate and the long term graft function in recipients. Recently, thanks to the introduction of new immunosuppression strategies, clinical data greatly improved: insulin independence was reached in all recipients and maintained in more than 70% of them 2 years from the transplant. The need of an immunosuppression therapy limits the indication of islet transplantation to diabetic patients already immunosuppressed for a previous organ transplant or to patients with brittle diabetes, that is not controlled also with the new strategies of insulin treatment, with a poor quality of life and an increased rate of diabetic complications. Other problems are represented by the progressive decrease of graft function during long term follow up, and by the low number of organ donors that limits the number of transplantation feasible per year.

AB - Islet transplantation was proposed more than 10 years ago as treatment for normalising glucose homeostasis in type 1 diabetic patients. Since the beginning it has aroused great interest among diabetic patients being an easy procedure, burdened by minor complications: islet transplantation in fact consists on a transhepatic percutaneous injection under local anaesthesia. The initial clinical outcomes not came up to expectations, being low the insulin independence rate and the long term graft function in recipients. Recently, thanks to the introduction of new immunosuppression strategies, clinical data greatly improved: insulin independence was reached in all recipients and maintained in more than 70% of them 2 years from the transplant. The need of an immunosuppression therapy limits the indication of islet transplantation to diabetic patients already immunosuppressed for a previous organ transplant or to patients with brittle diabetes, that is not controlled also with the new strategies of insulin treatment, with a poor quality of life and an increased rate of diabetic complications. Other problems are represented by the progressive decrease of graft function during long term follow up, and by the low number of organ donors that limits the number of transplantation feasible per year.

UR - http://www.scopus.com/inward/record.url?scp=0042916254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042916254&partnerID=8YFLogxK

M3 - Article

C2 - 12717341

AN - SCOPUS:0042916254

VL - 28

SP - 103

EP - 109

JO - Minerva Endocrinologica

JF - Minerva Endocrinologica

SN - 0391-1977

IS - 2

ER -